AR118777A2 - Neurotoxinas catiónicas - Google Patents
Neurotoxinas catiónicasInfo
- Publication number
- AR118777A2 AR118777A2 ARP200101165A ARP200101165A AR118777A2 AR 118777 A2 AR118777 A2 AR 118777A2 AR P200101165 A ARP200101165 A AR P200101165A AR P200101165 A ARP200101165 A AR P200101165A AR 118777 A2 AR118777 A2 AR 118777A2
- Authority
- AR
- Argentina
- Prior art keywords
- clostridial toxin
- amino acid
- acid modification
- designed
- neurotoxins
- Prior art date
Links
- 239000002581 neurotoxin Substances 0.000 title 1
- 231100000618 neurotoxin Toxicity 0.000 title 1
- 231100001102 clostridial toxin Toxicity 0.000 abstract 4
- 150000001413 amino acids Chemical class 0.000 abstract 3
- 230000004048 modification Effects 0.000 abstract 3
- 238000012986 modification Methods 0.000 abstract 3
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/04—Chelating agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24068—Tentoxilysin (3.4.24.68), i.e. tetanus neurotoxin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
La presente provee una toxina clostridial diseñada que comprende por lo menos una modificación de aminoácido, en donde dicha por lo menos una modificación de aminoácido incrementa el punto isoeléctrico (pI) de la 5 toxina clostridial diseñada llevándolo a un valor que es por lo menos 0,2 unidades de pI superior al pI de una toxina clostridial por demás idéntica que carezca de dicha por lo menos una modificación de aminoácido. También se proveen usos correspondientes de la toxina clostridial diseñada en terapia.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1312317.9A GB201312317D0 (en) | 2013-07-09 | 2013-07-09 | Cationic neurotoxins |
Publications (1)
Publication Number | Publication Date |
---|---|
AR118777A2 true AR118777A2 (es) | 2021-10-27 |
Family
ID=49033565
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP140102553A AR096869A1 (es) | 2013-07-09 | 2014-07-10 | Neurotoxinas catiónicas |
ARP200101165A AR118777A2 (es) | 2013-07-09 | 2020-04-24 | Neurotoxinas catiónicas |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP140102553A AR096869A1 (es) | 2013-07-09 | 2014-07-10 | Neurotoxinas catiónicas |
Country Status (24)
Country | Link |
---|---|
US (2) | US9920310B2 (es) |
EP (2) | EP3019190B1 (es) |
JP (4) | JP6850127B2 (es) |
KR (3) | KR102340476B1 (es) |
CN (2) | CN105492020B (es) |
AR (2) | AR096869A1 (es) |
AU (1) | AU2014288953C1 (es) |
CA (1) | CA2917009A1 (es) |
DK (1) | DK3019190T3 (es) |
EA (2) | EA202191745A1 (es) |
ES (1) | ES2881301T3 (es) |
GB (1) | GB201312317D0 (es) |
HK (1) | HK1222795A1 (es) |
HU (1) | HUE055733T2 (es) |
IL (3) | IL243330B (es) |
MX (2) | MX2016000047A (es) |
PL (1) | PL3019190T3 (es) |
PT (1) | PT3019190T (es) |
SA (1) | SA516370371B1 (es) |
SG (2) | SG11201600150UA (es) |
TW (3) | TWI694081B (es) |
UA (1) | UA126889C2 (es) |
WO (1) | WO2015004461A1 (es) |
ZA (1) | ZA201801413B (es) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201312317D0 (en) * | 2013-07-09 | 2013-08-21 | Syntaxin Ltd | Cationic neurotoxins |
EP3194426A2 (en) | 2014-08-12 | 2017-07-26 | Biomadison, Inc. | Botulinum neurotoxins with modified light chain specifity and methods for producing same |
US10647750B2 (en) | 2015-01-09 | 2020-05-12 | Ipsen Bioinnovation Limited | Cationic neurotoxins |
GB201517450D0 (en) * | 2015-10-02 | 2015-11-18 | Ipsen Biopharm Ltd | Method |
GB201607901D0 (en) * | 2016-05-05 | 2016-06-22 | Ipsen Biopharm Ltd | Chimeric neurotoxins |
MX2019000151A (es) * | 2016-07-08 | 2019-08-29 | Childrens Medical Center | Una neurotoxina botulinica novedosa y sus derivados. |
TW201814045A (zh) * | 2016-09-16 | 2018-04-16 | 英商艾普森生物製藥有限公司 | 製造雙鏈梭狀芽孢桿菌神經毒素之方法 |
EP3752128A1 (de) * | 2018-02-16 | 2020-12-23 | Bontana Therapies Gmbh | Nukleinsäure-basiertes botulinum neurotoxin zur therapeutischen anwendung |
US20220016221A1 (en) | 2018-12-05 | 2022-01-20 | Ipsen Biopharm Limited | Treatment of symptoms of traumatic brain injury |
GB201914034D0 (en) | 2019-09-30 | 2019-11-13 | Ipsen Biopharm Ltd | Treatment of neurological disorders |
GB202001353D0 (en) | 2020-01-31 | 2020-03-18 | Ipsen Biopharm Ltd | Treatment of skin conditions |
GB202003813D0 (en) | 2020-03-16 | 2020-04-29 | Ipsen Biopharm Ltd | Treatment of upper facial lines |
TWI825396B (zh) * | 2020-03-16 | 2023-12-11 | 英商艾普森生物製藥有限公司 | 肢體痙攣之治療 |
GB202011055D0 (en) | 2020-07-17 | 2020-09-02 | Ipsen Bioinnovation Ltd | Treatment of post-operative pain |
WO2022073360A1 (zh) * | 2020-10-10 | 2022-04-14 | 广州东盛生物科技有限公司 | 构建新型冠状病毒疫苗的方法及其应用 |
GB202100566D0 (en) | 2021-01-15 | 2021-03-03 | Ipsen Biopharm Ltd | Treatment of brain damage |
GB202103372D0 (en) | 2021-03-11 | 2021-04-28 | Ipsen Biopharm Ltd | Modified clostridial neurotoxins |
EP4297773A1 (en) | 2021-03-30 | 2024-01-03 | Ipsen Biopharm Limited | Catalytically inactive clostridial neurotoxins for the treatment of pain & inflammatory disorders |
JP2024513191A (ja) | 2021-03-30 | 2024-03-22 | イプセン バイオファーム リミテッド | 疼痛及び炎症性障害の処置 |
AU2022348206A1 (en) | 2021-09-16 | 2024-03-28 | Ipsen Biopharm Limited | Modified bont/a for use in the treatment of cervical dystonia |
CA3228712A1 (en) | 2021-09-23 | 2023-03-30 | Nicolae GRIGORE | Modified bont/a for use in the treatment of a disorder affecting an eyelid muscle of a subject |
GB202113602D0 (en) | 2021-09-23 | 2021-11-10 | Ipsen Biopharm Ltd | Treatment of a disorder affecting an eyelid muscle of a subject |
WO2023075060A1 (ko) * | 2021-10-25 | 2023-05-04 | 비피메드(주) | 보툴리눔 유래 펩타이드를 포함하는 통증개선용 조성물 |
GB202116795D0 (en) | 2021-11-22 | 2022-01-05 | Ipsen Biopharm Ltd | Treatment of visceral pain |
GB202206353D0 (en) | 2022-04-29 | 2022-06-15 | Ipsen Biopharm Ltd | Treatment of cervical dystonia |
GB202206348D0 (en) | 2022-04-29 | 2022-06-15 | Ipsen Biopharm Ltd | Treatment of limb spasticity |
GB202213479D0 (en) | 2022-09-14 | 2022-10-26 | Ipsen Biopharm Ltd | Cell-free clostridial neurotoxin assays |
CN115819526A (zh) * | 2022-12-02 | 2023-03-21 | 海雅美生物技术(珠海)有限公司 | 一种重组肉毒杆菌神经毒素及其制备方法和应用 |
Family Cites Families (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU3658093A (en) | 1992-02-10 | 1993-09-03 | Seragen, Inc. | Desensitization to specific allergens |
GB9305735D0 (en) | 1993-03-19 | 1993-05-05 | North John R | Novel agent for controlling cell activity |
DE69435254D1 (de) | 1993-06-10 | 2009-12-31 | Allergan Inc | Behandlung von neuromusculaeren Störungen und Zuständen mit verschiedenen botulism Serotypen |
US5437291A (en) | 1993-08-26 | 1995-08-01 | Univ Johns Hopkins | Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction |
WO2000067700A2 (en) * | 1999-05-12 | 2000-11-16 | United States Army Medical Research & Materiel Cmd | Recombinant vaccine against botulinum neurotoxin |
US6974578B1 (en) | 1993-12-28 | 2005-12-13 | Allergan, Inc. | Method for treating secretions and glands using botulinum toxin |
US20040126396A1 (en) | 1993-12-28 | 2004-07-01 | Allergan, Inc. | Botulinum toxin treatment for strabismus |
US5670484A (en) | 1994-05-09 | 1997-09-23 | Binder; William J. | Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders |
US5714469A (en) | 1994-09-01 | 1998-02-03 | Smithkline Beecham Corporation | Method of treating sepsis |
GB9508204D0 (en) | 1995-04-21 | 1995-06-07 | Speywood Lab Ltd | A novel agent able to modify peripheral afferent function |
US7192596B2 (en) | 1996-08-23 | 2007-03-20 | The Health Protection Agency Ipsen Limited | Recombinant toxin fragments |
GB9617671D0 (en) | 1996-08-23 | 1996-10-02 | Microbiological Res Authority | Recombinant toxin fragments |
US6063768A (en) | 1997-09-04 | 2000-05-16 | First; Eric R. | Application of botulinum toxin to the management of neurogenic inflammatory disorders |
GB9721189D0 (en) | 1997-10-08 | 1997-12-03 | Speywood Lab The Limited | Analgesic conjugates |
ATE227739T1 (de) | 1998-05-13 | 2002-11-15 | Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh | Hybridprotein zur hemmung der mastzelldegranulation und dessen verwendung |
EP1346731B1 (en) | 1998-07-22 | 2006-12-06 | Osprey Pharmaceuticals Limited | Conjugates for treating inflammatory disorders and associated tissue damage |
GB9818548D0 (en) | 1998-08-25 | 1998-10-21 | Microbiological Res Authority | Treatment of mucas hypersecretion |
US6776990B2 (en) | 1999-04-08 | 2004-08-17 | Allergan, Inc. | Methods and compositions for the treatment of pancreatitis |
US6358697B2 (en) | 1999-04-21 | 2002-03-19 | Children's Hospital Medical Center | Intracellular pharmaceutical targeting |
US6767544B2 (en) | 2002-04-01 | 2004-07-27 | Allergan, Inc. | Methods for treating cardiovascular diseases with botulinum toxin |
US6358917B1 (en) | 1999-08-24 | 2002-03-19 | Jean D. A. Carruthers | Cosmetic use of botulinum toxin for treatment of downturned mouth |
DE60032367T3 (de) | 1999-08-25 | 2011-03-10 | Allergan, Inc., Irvine | Aktivierbare rekombinante neurotoxine |
GB9922554D0 (en) | 1999-09-23 | 1999-11-24 | Microbiological Res Authority | Inhibition of secretion from non-neuronal cells |
US6113915A (en) | 1999-10-12 | 2000-09-05 | Allergan Sales, Inc. | Methods for treating pain |
US6265379B1 (en) | 1999-10-13 | 2001-07-24 | Allergan Sales, Inc. | Method for treating otic disorders |
US7838008B2 (en) | 1999-12-07 | 2010-11-23 | Allergan, Inc. | Methods for treating diverse cancers |
US6139845A (en) | 1999-12-07 | 2000-10-31 | Allergan Sales, Inc. | Method for treating cancer with a neurotoxin |
US6337075B1 (en) | 2000-01-11 | 2002-01-08 | Allergan Sales, Inc. | Methods for treating diabetes |
US6261572B1 (en) | 2000-01-11 | 2001-07-17 | Allergan Sales, Inc. | Method for treating a pancreatic disorder with a neurotoxin |
US6143306A (en) | 2000-01-11 | 2000-11-07 | Allergan Sales, Inc. | Methods for treating pancreatic disorders |
US6641820B1 (en) | 2000-01-19 | 2003-11-04 | Allergan, Inc. | Clostridial toxin derivatives and methods to treat pain |
US6524580B1 (en) | 2000-02-15 | 2003-02-25 | Allergan Sales, Inc. | Method for treating thyroid disorders |
US6464986B1 (en) | 2000-04-14 | 2002-10-15 | Allegan Sales, Inc. | Method for treating pain by peripheral administration of a neurotoxin |
US6299893B1 (en) | 2000-04-17 | 2001-10-09 | Marvin Schwartz | Method to reduce hair loss and stimulate hair regrowth |
US6565870B1 (en) | 2000-04-28 | 2003-05-20 | Allergan, Inc. | Methods for treating bone tumors |
US6306403B1 (en) | 2000-06-14 | 2001-10-23 | Allergan Sales, Inc. | Method for treating parkinson's disease with a botulinum toxin |
US6903187B1 (en) | 2000-07-21 | 2005-06-07 | Allergan, Inc. | Leucine-based motif and clostridial neurotoxins |
US6423319B1 (en) | 2000-10-04 | 2002-07-23 | Allergan Sales, Inc. | Methods for treating muscle injuries |
US6827931B1 (en) | 2000-10-20 | 2004-12-07 | Allergan, Inc. | Method for treating endocrine disorders |
US7273722B2 (en) | 2000-11-29 | 2007-09-25 | Allergan, Inc. | Neurotoxins with enhanced target specificity |
US20040028613A1 (en) | 2001-06-25 | 2004-02-12 | Nastech Pharmaceutical Company Inc | Dopamine agonist formulations for enhanced central nervous system delivery |
US6623742B2 (en) | 2001-09-17 | 2003-09-23 | Allergan, Inc. | Methods for treating fibromyalgia |
US7255866B2 (en) | 2001-09-17 | 2007-08-14 | Allergan, Inc. | Botulinum toxin therapy for fibromyalgia |
US6921538B2 (en) | 2002-05-10 | 2005-07-26 | Allergan, Inc. | Therapeutic treatments for neuropsychiatric disorders |
EP1551430A2 (en) | 2002-10-15 | 2005-07-13 | Allergan, Inc. | Botulinum toxin dental therapies and procedures |
US7238357B2 (en) | 2002-11-05 | 2007-07-03 | Allergan, Inc. | Methods for treating ulcers and gastroesophageal reflux disease |
US7166575B2 (en) | 2002-12-17 | 2007-01-23 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity |
US8071550B2 (en) | 2003-03-03 | 2011-12-06 | Allergan, Inc. | Methods for treating uterine disorders |
US6838434B2 (en) | 2003-05-02 | 2005-01-04 | Allergan, Inc. | Methods for treating sinus headache |
US7220422B2 (en) | 2003-05-20 | 2007-05-22 | Allergan, Inc. | Methods and compositions for treating eye disorders |
US20040253274A1 (en) | 2003-06-11 | 2004-12-16 | Allergan, Inc. | Use of a clostridial toxin to reduce appetite |
DE102004043009A1 (de) | 2004-09-06 | 2006-03-23 | Toxogen Gmbh | Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen |
EP1830872B1 (en) | 2004-12-01 | 2010-11-17 | Health Protection Agency | Fusion proteins |
JP2008531732A (ja) * | 2005-03-03 | 2008-08-14 | ルバンス セラピュティックス インク. | ボツリヌス毒素の局所塗布及び経皮送達のための組成物及び方法 |
AU2006227816B2 (en) * | 2005-03-15 | 2012-04-05 | Allergan, Inc. | Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems |
DE102005019302A1 (de) | 2005-04-26 | 2006-11-16 | Toxogen Gmbh | Carrier zum Targeting von Nervenzellen |
ATE463506T1 (de) | 2005-09-19 | 2010-04-15 | Allergan Inc | Mit clostriedientoxin aktivierbare clostridientoxine |
EP1834962A1 (de) | 2006-03-15 | 2007-09-19 | Biotecon Therapeutics GmbH | PEGyliertes mutiertes Clostridium botulinum Toxin |
AU2007347781B2 (en) * | 2006-07-11 | 2013-10-03 | Allergan, Inc. | Modified clostridial toxins with enhanced translocation capability and enhanced targeting activity |
EP2178905B1 (en) * | 2007-07-26 | 2013-11-06 | Allergan, Inc. | Methods of activiting clostridial toxins |
WO2009015840A2 (en) * | 2007-07-27 | 2009-02-05 | Merz Pharma Gmbh & Co. Kgaa | Polypeptide for targeting of neural cells |
US8445650B2 (en) * | 2007-09-25 | 2013-05-21 | Thomas Jefferson University | Mutant botulinum neurotoxin serotype A polypeptide and uses thereof |
SG185338A1 (en) * | 2007-10-23 | 2012-11-29 | Allergan Inc | Methods of treating urogenital-neurological disorders using modified clostridial toxins |
PL2379104T3 (pl) * | 2008-12-31 | 2018-07-31 | Revance Therapeutics, Inc. | Preparaty toksyny botulinowej do wstrzykiwania |
GB0903006D0 (en) | 2009-02-23 | 2009-04-08 | Syntaxin Ltd | Modified non-cytotoxic proteases |
JP5764550B2 (ja) | 2009-04-14 | 2015-08-19 | エムシーダブリユー リサーチ フオンデーシヨン インコーポレーテツド | 遺伝子工学的ボツリヌス神経毒 |
JP4900443B2 (ja) | 2009-09-30 | 2012-03-21 | 大日本印刷株式会社 | 色素増感型太陽電池 |
ES2600463T3 (es) * | 2010-05-20 | 2017-02-09 | Allergan, Inc. | Toxinas clostridiales degradables |
US8853360B2 (en) | 2010-06-23 | 2014-10-07 | Wisconsin Alumni Research Foundation | Engineered botulinum neurotoxin C1 with selective substrate specificity |
US20120189677A1 (en) | 2011-01-20 | 2012-07-26 | Stephen Tonge | Formulations |
BR112014011137A2 (pt) * | 2011-11-09 | 2018-06-12 | Merz Pharma Gmbh & Co Kgaa | polinucleotídeo, vetor, célula hospedeira, polipeptídeo, anticorpo, método para a produção de um polipeptídeo, método para a produção de um medicamento |
PT2854840T (pt) | 2012-05-30 | 2018-03-02 | Harvard College | Neurotoxina botulínica geneticamente modificada |
GB201312317D0 (en) * | 2013-07-09 | 2013-08-21 | Syntaxin Ltd | Cationic neurotoxins |
GB201407525D0 (en) * | 2014-04-29 | 2014-06-11 | Syntaxin Ltd | Manufacture of recombinant clostridium botulinum neurotoxins |
-
2013
- 2013-07-09 GB GBGB1312317.9A patent/GB201312317D0/en not_active Ceased
-
2014
- 2014-07-09 TW TW103123643A patent/TWI694081B/zh active
- 2014-07-09 WO PCT/GB2014/052097 patent/WO2015004461A1/en active Application Filing
- 2014-07-09 KR KR1020167003051A patent/KR102340476B1/ko active IP Right Grant
- 2014-07-09 AU AU2014288953A patent/AU2014288953C1/en active Active
- 2014-07-09 TW TW111118323A patent/TWI813291B/zh active
- 2014-07-09 EA EA202191745A patent/EA202191745A1/ru unknown
- 2014-07-09 KR KR1020217040836A patent/KR102617830B1/ko active IP Right Grant
- 2014-07-09 EP EP14747697.2A patent/EP3019190B1/en active Active
- 2014-07-09 PT PT147476972T patent/PT3019190T/pt unknown
- 2014-07-09 US US14/903,458 patent/US9920310B2/en active Active
- 2014-07-09 DK DK14747697.2T patent/DK3019190T3/da active
- 2014-07-09 CN CN201480043806.7A patent/CN105492020B/zh active Active
- 2014-07-09 SG SG11201600150UA patent/SG11201600150UA/en unknown
- 2014-07-09 HU HUE14747697A patent/HUE055733T2/hu unknown
- 2014-07-09 EA EA201690189A patent/EA039105B1/ru unknown
- 2014-07-09 TW TW109114599A patent/TWI776147B/zh active
- 2014-07-09 CN CN202110239457.8A patent/CN112961227A/zh active Pending
- 2014-07-09 MX MX2016000047A patent/MX2016000047A/es unknown
- 2014-07-09 PL PL14747697T patent/PL3019190T3/pl unknown
- 2014-07-09 ES ES14747697T patent/ES2881301T3/es active Active
- 2014-07-09 JP JP2016524894A patent/JP6850127B2/ja active Active
- 2014-07-09 CA CA2917009A patent/CA2917009A1/en active Pending
- 2014-07-09 UA UAA201601094A patent/UA126889C2/uk unknown
- 2014-07-09 KR KR1020237044106A patent/KR20240005140A/ko active Application Filing
- 2014-07-09 EP EP21167912.1A patent/EP3943105A3/en active Pending
- 2014-07-09 SG SG10202005416PA patent/SG10202005416PA/en unknown
- 2014-07-10 AR ARP140102553A patent/AR096869A1/es unknown
-
2015
- 2015-12-24 IL IL243330A patent/IL243330B/en active IP Right Grant
-
2016
- 2016-01-07 MX MX2021006714A patent/MX2021006714A/es unknown
- 2016-01-07 SA SA516370371A patent/SA516370371B1/ar unknown
- 2016-09-20 HK HK16111009.8A patent/HK1222795A1/zh unknown
-
2018
- 2018-02-06 US US15/889,317 patent/US11034947B2/en active Active
- 2018-03-01 ZA ZA2018/01413A patent/ZA201801413B/en unknown
-
2019
- 2019-04-01 JP JP2019069960A patent/JP7360802B2/ja active Active
- 2019-11-19 IL IL270769A patent/IL270769B/en active IP Right Grant
-
2020
- 2020-04-24 AR ARP200101165A patent/AR118777A2/es unknown
- 2020-08-25 IL IL276915A patent/IL276915B/en unknown
-
2021
- 2021-12-21 JP JP2021206753A patent/JP7434263B2/ja active Active
-
2024
- 2024-02-07 JP JP2024016868A patent/JP2024054234A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR118777A2 (es) | Neurotoxinas catiónicas | |
BR112017028318A2 (pt) | compostos antibacterianos | |
AU2017260389A1 (en) | Chimeric neurotoxins | |
EA201690314A1 (ru) | Анти-garp-белок и его применения | |
CL2016002971A1 (es) | Combinación. | |
BR112019004785A2 (pt) | variantes de alfa-glicosidase ácida e usos das mesmas | |
BR112016027871A2 (pt) | composição para melhorar a memória, a função de aprendizado e/ou função cognitiva | |
CR20140421A (es) | Cepa plaguicida de flavobacterium y composiciones bioactivas, metabolitos y usos de la misma | |
BR112015028853A2 (pt) | Composição detergente com ph baixo | |
BR112015021269A2 (pt) | peptídeos e composições para tratamento de dano articular | |
CR20170425A (es) | Nuevas proteínas específicas para pioverdina y pioquelina | |
BR112019004783A2 (pt) | variantes de alfa-glicosidase ácida e usos das mesmas | |
PH12014502762A1 (en) | Method for the degradation of keratin and use of the keratin hydrolysate produced | |
PE20151435A1 (es) | Laquinimod para reducir el dano talamico en la esclerosis multiple | |
IN2014DN10710A (es) | ||
MX2014010959A (es) | Preparaciones de ester de acido fosforico con higroscopia reducida. | |
BR112016003671A2 (pt) | gene de resistência a ferrugem | |
TR201905787T4 (tr) | Liyofilize TAT-NR2B9C formülasyonu. | |
MX2017012596A (es) | Una composicion farmaceutica y el uso de la misma. | |
UY35463A (es) | Formulaciones de polipéptido fc-factor ix. | |
BR112017016895A2 (pt) | processo de produção de gonadotrofina | |
CL2015001502A1 (es) | Composición farmacéutica que comprende desloratadina y prendnisolona y uso de la misma. | |
BR112019006956A2 (pt) | ketchup de tomate com estabilidade de armazenamento aperfeiçoada | |
BR112018075078A2 (pt) | modificação de polipeptídeos da hemaglutinina do influenza manipulados | |
UY34267A (es) | Métodos para aumentar el contenido de proteínas,aceites y/o aminoácidos en una planta |